Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy.
Joan Miguel Romero, Jamie Magrill, Nikita Kalashnikov et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis compared patient-derived xenografts (PDX) and patient-derived organoids (PDO) in predicting treatment response in cancer patients. Analyzing 411 patient-model pairs, the study found an overall concordance in treatment response of 70%, with no significant differences between PDX and PDO. The findings suggest that PDO may serve as effective alternatives to PDX in certain contexts.
Key findings
- Overall concordance in treatment response between patients and models was 70%.
- Sensitivity, specificity, and predictive values were comparable between PDX and PDO.
- Patients with responding PDO had prolonged progression-free survival.
- For PDX, the association with progression-free survival was significant only in low bias risk pairs.
Why it matters
Understanding the predictive accuracy of PDX and PDO models is crucial for optimizing cancer treatment strategies. This study highlights the potential of PDO as a viable alternative to PDX, which may influence future research and clinical applications.